Skip to main content

Table 2 Cox proportional hazards model for disease-free and overall survivals of 254 patients with EOC

From: BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

DFSUnivariate HR (95% CI)bpMultivariate HR (95% CI)bpOSUnivariate HR (95% CI)bpMultivariate HR (95% CI)bp
FIGO stage [advanced/early]3.6 (2.2–5.8)< 0.0012.3 (1.3–4.2)0.004FIGO stage [advanced/early]2.6 (1.3–4.8)0.0041.3 (0.6–2.7)0.53
Histology [serous/non-serousa]1.5 (1.1–2.2)0.011.1 (0.8–1.6)0.63Histology [serous/non-serousa]1.1 (0.7–1.7)0.74  
Tumor grade [3/1–2]2.0 (1.1–3.4)0.0151.6 (0.9–2.8)0.11Tumor grade [3/1–2]1.4 (0.7–2.9)0.39  
Postoperative residual tumor [≥1 cm/< 1 cm]2.8 (2.1–3.9)< 0.0012.1 (1.4–2.9)< 0.001Postoperative residual tumor [> 1 cm/<  1 cm]3.1 (2.0–5.0)< 0.0012.7 (1.6–4.7)< 0.001
BTLA expression [detectable/non- detectable]2.0 (1.4–2.9)< 0.0011.7 (1.2–2.4)0.002BTLA expression [detectable/non- detectable]2.0 (1.2–3.5)0.0091.8 (1.04–3.0)0.035
  1. Abbreviations: EOC epithelial ovarian carcinoma; DFS disease-free survival; OS overall survival; HR Hazard ratio; CI confidence interval; FIGO International Federation of Gynecology and Obstetrics; BTLA B and T lymphocyte attenuator
  2. aNon-serous includes mucinous, clear cell, endometrioid, and undifferentiated types
  3. bCox regression model